phosphoserine and GDC-0623

phosphoserine has been researched along with GDC-0623 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anderson, DJ; Belvin, M; Chan, J; Chen, H; Friedman, LS; Haling, JR; Hatzivassiliou, G; Heald, R; Hewitt, JF; Hoeflich, KP; Ludlam, MJ; Luoh, SM; Malek, S; Merchant, M; Orr, C; Peck, A; Price, S; Song, K; Ultsch, M; Wiesmann, C; Zak, M	1

Other Studies

1 other study(ies) available for phosphoserine and GDC-0623

Article	Year
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature, 2013, Sep-12, Volume: 501, Issue:7466 Topics: Allosteric Regulation; Azetidines; Cell Survival; Clinical Trials as Topic; Crystallography, X-Ray; Enzyme Activation; Feedback, Physiological; Genes, ras; HCT116 Cells; Humans; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Neoplasms; Niacinamide; Oncogene Protein p21(ras); Phosphorylation; Phosphoserine; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf	2013

Article

Year

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.

Nature, 2013, Sep-12, Volume: 501, Issue:7466

Topics: Allosteric Regulation; Azetidines; Cell Survival; Clinical Trials as Topic; Crystallography, X-Ray; Enzyme Activation; Feedback, Physiological; Genes, ras; HCT116 Cells; Humans; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Neoplasms; Niacinamide; Oncogene Protein p21(ras); Phosphorylation; Phosphoserine; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf

2013